LLY

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

• Lilly’s Olomorasib Receives FDA Breakthrough Therapy Designation for First-Line Treatment of KRAS G12C-Mutant Metastatic Non-Small Cell Lung CancerSep 4, 2025

News

• FDA clears Eli Lilly's Jaypirca as a first-line treatment for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphomaOct 6, 2026
• Eli Lilly expands its collaboration with Gate Bioscience in a deal potentially worth more than $870 million to develop a new drug classOct 5, 2026
• Eli Lilly strengthens its next-generation obesity treatment strategy with new data from the EloraTZP combination therapyOct 1, 2026
• Eli Lilly reports additional data on triple G agonist retatrutide, strengthening its clinical profile in cardiometabolic diseasesSep 30, 2026
• Lilly launches the Change the Course Commitment to address treatment gaps in diabetes and obesity across low- and middle-income countriesSep 28, 2026